Antiretroviral Therapy With Atazanavir Therapeutics
1. Reyataz patent expiration
Treatment: Method for treating hiv-1 infection
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5849911 | BRISTOL MYERS SQUIBB | Antivirally active heterocyclic azahexane derivatives |
Jun, 2017
(8 years ago) | |
| US6087383 | BRISTOL MYERS SQUIBB | Bisulfate salt of HIV protease inhibitor |
Dec, 2018
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5849911 | BRISTOL MYERS SQUIBB | Antivirally active heterocyclic azahexane derivatives |
Jun, 2017
(8 years ago) | |
| US6087383 | BRISTOL MYERS SQUIBB | Bisulfate salt of HIV protease inhibitor |
Dec, 2018
(7 years ago) | |
|
US5849911 (Pediatric) | BRISTOL MYERS SQUIBB | Antivirally active heterocyclic azahexane derivatives |
Dec, 2017
(8 years ago) | |
|
US6087383 (Pediatric) | BRISTOL MYERS SQUIBB | Bisulfate salt of HIV protease inhibitor |
Jun, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-116) | Sep 30, 2011 |
| New Dosing Schedule(D-130) | Feb 04, 2014 |
| New Product(NP) | Jun 02, 2017 |
| New Patient Population(NPP) | Sep 24, 2018 |
| Pediatric Exclusivity(PED) | Mar 24, 2019 |
Drugs and Companies using ATAZANAVIR SULFATE ingredient
Market Authorisation Date: 20 June, 2003
Dosage: CAPSULE; POWDER
How can I launch a generic of REYATAZ before it's drug patent expiration?
More Information on Dosage
REYATAZ family patents
